Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...

Healthcare-associated infections (HAIs) pose a persistent and tremendous threat to patient safety, having claimed 72,000 patients during their hospitalization according to the Centers for Disease ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Biomet fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded today ...

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images.

Inc. reported robust financial results for the fourth quarter of 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.31, slightly above the forecast of $2.30. The company's ...

Hansa Biopharma reported its Q4 2024 earnings, revealing a larger-than-expected loss and lower-than-forecast revenue. The company posted an EPS of -4.08, significantly missing the forecast of -1.98, ...